RG0401 / RheumaGen - LARVOL DELTA

RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases (PRNewswire) - "RheumaGen, Inc...announced today the close of a $15 million Series A financing co-led by SPRIM Global Investments and William Taylor Nominees. The financing will support RheumaGen in completing a Phase I clinical trial of its lead program, RG0401, for treatment-resistant or refractory rheumatoid arthritis (RA)."

Financing • Rheumatoid Arthritis